0 seconds of 3 minutes, 50 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
00:00
03:50
03:50
 
  • Algernon Pharmaceuticals  (AGN) has filed a pre-IND meeting request with the U.S. Food and Drug Administration
  • Algernon is planning a phase 2 study of NP-120 (Ifenprodil) for the treatment of chronic cough
  • Algernon could begin its phase 2 chronic cough study as early as Q2 of 2022
  • Algernon is a clinical-stage pharmaceutical development company that investigates safe, approved drugs for new disease applications
  • Algernon Pharmaceuticals Inc. (AGN) opened trading at C$0.08 per share

Algernon Pharmaceuticals  (AGN) has filed a pre-IND meeting request with the U.S. Food and Drug Administration.

Algernon is planning a phase 2 study of NP-120 (Ifenprodil) for the treatment of chronic cough. Ifenprodil is an NMDA GluN2B subunit inhibitor and may represent a potential treatment for chronic cough.

Depending on the feedback from the U.S. FDA, the company could begin its phase 2 chronic cough study as early as Q2 of 2022. 

“This submission to the U.S. FDA underscores our commitment to patients with refractory chronic cough,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals Inc.

“Many of these patients experience a significant negative impact on their quality of life, and there are currently no approved treatments.”

Algernon is a clinical-stage pharmaceutical development company that investigates safe, approved drugs for new disease applications.

Algernon Pharmaceuticals Inc. (AGN) opened trading at C$0.08 per share.

More From The Market Online
ai generated stock image

@ the Bell: Markets stumble into the weekend

Canada’s main stock index faced challenges on Friday as commodity prices declined and mixed signals from US-China trade discussions.
ai generated stock image

@ the Bell: Ongoing tariff drama erodes market confidence

Canada’s main stock index was subdued on Thursday as traders assessed risks of the US administration's fluctuating stance on tariffs.
BriaCell logo

BriaCell’s Bria-OTS shows sustained success against breast cancer

BriaCell (TSX:BCT) announces the resolution of the lung metastasis first reported in February in a 78-year-old woman with breast cancer.
The Market Online Video

Trade Wars, Soaring Gold, and Canada’s Political Crossroads

The Canadian Securities Exchange presents your go-to source for trends in junior and small cap markets each month.
  • Research
  • 14 mins
  • 24 April 2025 07:39 (EDT)